One of the primary challenges in modern immunology and epidemiology is the rapid mutation of pathogens and the static nature of existing vaccines, which renders them less effective against highly mutable pathogens. Traditional vaccination strategies often fail to keep pace with the evolution of viral pathogens, subjecting the global healthcare system to constant and escalating threats.
“Influenza viruses, coronaviruses, and Ebola-group viruses are undergoing constant mutation. By the time new vaccines become widely available, they may have a diminished protective effect against circulating strains. The current ‘reactive’ vaccination system is unable to keep up with this pace,” noted Professor Saul Faust of the University of Southampton, co-author of the initiative.
In response to this challenge, scientists from the Universities of Cambridge and Southampton have developed the world’s first AI-designed universal vaccine. This vaccine provides long-lasting protection against a broad spectrum of viruses, such as Ebola or the coronavirus group, regardless of viral mutation. The vaccine has already been successfully tested in clinical trials. Professor Jonathan Heeney, head of the Laboratory of Viral Zoonotics at the University of Cambridge and scientific lead of the study, noted that this new class of universal vaccines could potentially protect humans against viruses that have not yet been identified.
The aim of the research was to create a universal vaccine capable of providing broad and durable immune protection not only against known viral strains but also against future emerging genetic variants. This approach fundamentally differs from traditional vaccine design and development principles, which are typically tailored to a specific strain or a single variant thereof.
At the core of the study was an AI-generated “super-antigen”—a synthetic protein that replicates common structural markers characteristic of various coronavirus strains. Rather than targeting one specific strain, it activates the immune system and directs the immune response against a broad spectrum of pathogens that share these common features.
Using machine learning algorithms, scientists analyzed a database of genetic sequences of Sarbecoviruses (a subgenus of Betacoronavirus known for causing respiratory viruses, including SARS-CoV-1 and SARS-CoV-2/COVID-19). These viruses primarily circulate in bats but can, under certain conditions, spread to humans and other mammals. Based on the data obtained, an antigen was created capable of large-scale immune system activation and the generation of an immune response against a wide range of viruses, irrespective of their subsequent genetic evolution.
The vaccine administration method is also innovative. Instead of a traditional needle, a microfluidic flow system is used, delivering the antigen into the skin via a high-velocity liquid jet. This technology reduces medical waste, improves vaccine accessibility, and is particularly significant for low- and middle-income countries where cold-chain infrastructure is often inadequate.
In the first phase of clinical trials, conducted from December 2021 to September 2023, 39 volunteers participated. No significant or serious adverse events were reported regarding the vaccine’s safety. In the near future, scientists plan to initiate the second phase of clinical trials.
This achievement represents significant progress toward replacing the “passive” immunization model with a “proactive,” future-oriented strategy. The results of subsequent clinical trials will determine the practical significance of this innovative technological platform and its potential to play a major role in the prevention and control of future pandemics.
Source: euronews.com
